VERAXA Biotech has initiated cell line development for its lead BiTAC-TCE cancer therapy program by partnering with ATUM, a US-based biotech CRO. This collaboration uses ATUM's Leap-In Transposase® technology to create stable clonal cell lines essential for manufacturing and clinical development. VERAXA's BiTAC-TCE approach aims to improve tumor targeting and reduce side effects by activating T-cell engagement only when two tumor markers are present, potentially widening the therapeutic window. This step advances VERAXA's program toward IND/CTA-enabling activities and future clinical trials.
AngioDynamics reported an 8% revenue increase to $86.6 million in Q4, driven by a 16.7% sales rise in its Med Tech division, notably from NanoKnife and AlphaVac products. H.C. Wainwright raised the price target from $16 to $19 and maintained a Buy ra...
PNC Financial Services Group reported Q2 2026 adjusted EPS of $4.85 and record revenue of $6.88 billion, surpassing analyst expectations. The growth was driven by a 15.5% rise in net interest income and a 31.4% increase in fee income, reflecting stro...
Greenlight, a leading cannabis operator, expanded its Ohio presence by opening four new dispensaries and adding in-state manufacturing, reaching the state's maximum allowed eight dispensaries. This move strengthens Greenlight's position in Ohio's lim...
Halper Sadeh LLC is investigating whether shareholders of Element Solutions Inc (ESI), Crinetics Pharmaceuticals (CRNX), and Solstice Advanced Materials (SOLS) are receiving fair treatment in their respective sale and merger transactions. The firm hi...
Investment banks Scotiabank and Bernstein have lowered their price targets for Comcast due to increased competition from new players like SpaceX's Starlink and valuation risks. Comcast is also undergoing a major strategic shift by spinning off its NB...
